Industry News
Biotechnology Industry News
Passage Bio chips away at workforce, prioritizes R&D with UPenn’s James Wilson
Passage Bio chips away at workforce, prioritizes R&D with UPenn's James Wilson mbayer Tue, 03/15/2022 - 10:09
AbbVie, eyeing shift to endemic, adds to COVID-19 work with Scripps partnership
AbbVie, eyeing shift to endemic, adds to COVID-19 work with Scripps partnership klahucik Tue, 03/15/2022 - 09:54
Pfizer cancer vaccine science chief poached by Gilead-backed Shoreline Biosciences
Pfizer cancer vaccine science chief poached by Gilead-backed Shoreline Biosciences klahucik Tue, 03/15/2022 - 08:59
Astellas’ menopause drug suffers rare setback as failed Asian trial blots previously pristine record
Astellas' menopause drug suffers rare setback as failed Asian trial blots previously pristine record ntaylor Tue, 03/15/2022 - 07:43
AnaptysBio’s ACORN fails to grow mighty oak, marking end of development of imsidolimab in acne
AnaptysBio's ACORN fails to grow mighty oak, marking end of development of imsidolimab in acne ntaylor Tue, 03/15/2022 - 06:41
Moderna hits the gas as it begins dosing of 2nd HIV vaccine
Moderna hits the gas as it begins dosing of 2nd HIV vaccine mbayer Mon, 03/14/2022 - 15:02
‘Biotech sisterhood’: 25 female CEOs find new ways to ‘sponsor’ the next generation at Arizona retreat
'Biotech sisterhood': 25 female CEOs find new ways to 'sponsor' the next generation at Arizona retreat klahucik Mon, 03/14/2022 - 12:27
CAMP4 poaches Translate Bio medical chief, adds ex-Biogen R&D leader Al Sandrock to advisory board
CAMP4 poaches Translate Bio medical chief, adds ex-Biogen R&D leader Al Sandrock to advisory board klahucik Mon, 03/14/2022 - 11:22
Ascendis scores in phase 3 trial as it looks to expand endocrine-focused portfolio
Ascendis scores in phase 3 trial as it looks to expand endocrine-focused portfolio mbayer Mon, 03/14/2022 - 09:44
BMS-Nektar’s Opdivo combo fails phase 3 in upset to once-largest licensing deal in biotech history
BMS-Nektar's Opdivo combo fails phase 3 in upset to once-largest licensing deal in biotech history klahucik Mon, 03/14/2022 - 08:18
Long wait for pivotal data on Sanofi’s oral SERD ends in failure
Long wait for pivotal data on Sanofi's oral SERD ends in failure ntaylor Mon, 03/14/2022 - 07:25
BridgeBio plots path to market for muscular dystrophy drug after posting phase 2 data
BridgeBio plots path to market for muscular dystrophy drug after posting phase 2 data ntaylor Mon, 03/14/2022 - 06:33
Nutcracker snags $167M series C to develop ‘push-button’ RNA manufacturing, signs on former Gilead CFO
Nutcracker snags $167M series C to develop 'push-button' RNA manufacturing, signs on former Gilead CFO klahucik Fri, 03/11/2022 - 13:13
Concert tunes pipeline by selling off CNS assets to startup Terran Biosciences
Concert tunes pipeline by selling off CNS assets to startup Terran Biosciences klahucik Fri, 03/11/2022 - 10:46
Immunome’s COVID-19 antibody cocktail back on track for phase 1 after FDA lifts hold
Immunome's COVID-19 antibody cocktail back on track for phase 1 after FDA lifts hold mbayer Fri, 03/11/2022 - 09:34
AbbVie doubles down on Gedeon Richter pact that brought Vraylar to the world
AbbVie doubles down on Gedeon Richter pact that brought Vraylar to the world aarmstrong Fri, 03/11/2022 - 08:56
Histogen seeks to tear up COVID-19 R&D pact and go solo, accuses Amerimmune of failing to push on into phase 2
Histogen seeks to tear up COVID-19 R&D pact and go solo, accuses Amerimmune of failing to push on into phase 2 ntaylor Fri, 03/11/2022 - 06:31
Harpoon drug sunk by modest activity, challenging tolerability, forcing pivot from prostate cancer prospect
Harpoon drug sunk by modest activity, challenging tolerability, forcing pivot from prostate cancer prospect ntaylor Fri, 03/11/2022 - 03:54
Orphazyme on last leg as court-mediated restructuring drives another wave of layoffs
Orphazyme on last leg as court-mediated restructuring drives another wave of layoffs mbayer Thu, 03/10/2022 - 18:31
Chutes & Ladders—Janssen’s US oncology lead jumps to Teon as CEO
Chutes & Ladders—Janssen's US oncology lead jumps to Teon as CEO klahucik Thu, 03/10/2022 - 15:40